home / news & insights /
Lindenbaum is pleased to announce that it is further expanding its antitrust litigation practice with the arrival of Simon Mineur (associate) and Niels Wessel (paralegal).
Antitrust litigation head Stefan Tuinenga commented: “We are very happy to have Simon and Niels on board to play an important role in our expanding practice. They are very talented lawyers who have a particular interest in antitrust damages litigation in the Netherlands and will greatly contribute with their expertise and unique perspectives”.
Simon has extensive experience in antitrust litigation, both on the defense as the plaintiff side. He worked at a large Dutch tier-one defense firm, before gaining broad in-house experience as legal counsel at a large multinational corporate. Simon commented: “I am very pleased with the opportunity to further develop my skills at Lindenbaum. Their strategic approach informed by vast experience and expertise will make a difference where it matters, and I am looking forward to playing my part in that.”
Niels obtained a master’s degree in competition law and a bachelor’s degree in economics and business economics. His master’s thesis on the attractiveness of the Netherlands as a jurisdiction for antitrust damages cases was nominated for the best thesis award at the Dutch Mededingingscongres (competition conference). Niels commented: “I am delighted to become a part of the Lindenbaum team. Lindenbaum possesses outstanding litigation experience and expertise, and having the opportunity to work with them will have a profound effect on my further development.”
25 September 2024 - Insights
Lindenbaum is moving to its new Amsterdam offices at Concertgebouwplein 13. We look forward to meeting you there.
Read more5 September 2024 - Insights
Lindenbaum's managing partner Damiën Berkhout provided legal and governance advice to the management board of Beequip in the context of the transaction between NIBC and Apollo.
Read more5 September 2024 - News
The Amsterdam District Court ruled that the representative organization Stichting Farma Ter Verantwoording is admissible in its collective action against pharmaceutical giant AbbVie. The case now moves on to the merits phase, in which the court will assess whether Abbvie abused its dominant position and violated human rights by charging excessive prices for its Humira medicine.
Read more